Her2-positive breast cancer: Herceptin and beyond

This publication has 56 references indexed in Scilit:

• HER2/neu role in breast cancer: from a prognostic foe to a predictive friend
  Current Opinion in Obstetrics and Gynecology, 2007
• Kinetics of serum HER‐2/neu changes in patients with HER‐2‐positive primary breast cancer after initiation of primary chemotherapy
  Cancer, 2006
• HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy
  Oncogene, 2006
• Cancer Statistics, 2006
  CA: A Cancer Journal for Clinicians, 2006
• Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
  Breast Cancer Research, 2005
• Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors
  Science, 2004
• Herceptin acts as an anti-angiogenic cocktail
  Nature, 2002
• Mechanism of action of trastuzumab and scientific update
  Seminars in Oncology, 2001
• ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
  The EMBO Journal, 1997
• Proto-Oncogenes and Human Cancers
  New England Journal of Medicine, 1987